HC Wainwright Increases Enliven Therapeutics (NASDAQ:ELVN) Price Target to $39.00

Enliven Therapeutics (NASDAQ:ELVN - Free Report) had its price objective raised by HC Wainwright from $37.00 to $39.00 in a research note released on Friday morning,Benzinga reports. HC Wainwright currently has a buy rating on the stock.

Separately, BTIG Research assumed coverage on shares of Enliven Therapeutics in a research report on Friday, December 13th. They set a "buy" rating and a $42.00 price objective on the stock. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Buy" and a consensus target price of $38.75.

Enliven Therapeutics Stock Up 5.8 %

Shares of Enliven Therapeutics stock traded up $1.22 during trading on Friday, reaching $22.30. 75,455 shares of the stock were exchanged, compared to its average volume of 268,608. The firm has a market cap of $1.09 billion, a price-to-earnings ratio of -11.74 and a beta of 1.04. Enliven Therapeutics has a 1 year low of $15.96 and a 1 year high of $30.03. The stock's fifty day moving average is $21.31 and its 200 day moving average is $23.78.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last issued its quarterly earnings data on Thursday, March 13th. The company reported ($0.46) earnings per share for the quarter, topping analysts' consensus estimates of ($0.53) by $0.07. The business had revenue of $0.03 million during the quarter. Equities analysts forecast that Enliven Therapeutics will post -1.95 earnings per share for the current year.

Remove Ads

Insider Activity at Enliven Therapeutics

In other news, CEO Samuel Kintz sold 12,500 shares of the business's stock in a transaction on Monday, March 17th. The shares were sold at an average price of $20.83, for a total transaction of $260,375.00. Following the sale, the chief executive officer now owns 990,392 shares in the company, valued at approximately $20,629,865.36. The trade was a 1.25 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Benjamin Hohl sold 1,000 shares of the stock in a transaction dated Friday, January 3rd. The stock was sold at an average price of $25.04, for a total transaction of $25,040.00. Following the completion of the transaction, the chief financial officer now owns 13,000 shares of the company's stock, valued at approximately $325,520. The trade was a 7.14 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 72,784 shares of company stock worth $1,610,375 over the last ninety days. 29.20% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Enliven Therapeutics

Large investors have recently made changes to their positions in the business. Wellington Management Group LLP increased its stake in Enliven Therapeutics by 15.3% during the 4th quarter. Wellington Management Group LLP now owns 80,916 shares of the company's stock valued at $1,821,000 after purchasing an additional 10,746 shares in the last quarter. California State Teachers Retirement System raised its holdings in Enliven Therapeutics by 10.2% in the 4th quarter. California State Teachers Retirement System now owns 20,914 shares of the company's stock worth $471,000 after purchasing an additional 1,940 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in Enliven Therapeutics by 67.1% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 43,714 shares of the company's stock valued at $984,000 after purchasing an additional 17,546 shares in the last quarter. Stempoint Capital LP bought a new stake in Enliven Therapeutics during the fourth quarter valued at about $2,176,000. Finally, Polar Capital Holdings Plc grew its holdings in Enliven Therapeutics by 267.6% during the fourth quarter. Polar Capital Holdings Plc now owns 2,389,668 shares of the company's stock valued at $53,768,000 after purchasing an additional 1,739,668 shares during the period. 95.08% of the stock is currently owned by hedge funds and other institutional investors.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.